Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...
The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...
The 24 pathogen families listed in the reference tool include microorganisms that cause Covid-19 and Nipah virus, among ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback